Hangzhou Tigermed Consulting

Hangzhou Tigermed Consulting

300347 · SHE · Healthcare / Diagnostics & Research

47.88CNY-1.03 (-2.11%)

Price History

Full chart

Market Stats

Previous Close48.91
Open48.91
Day Range47.16 – 48.91
52-Week Range35.47 – 67.65
Volume8.95M
Market Cap50.28B
P/E (TTM)530.91
Forward P/E28.99
EPS0.11
Dividend Yield0.22%
Beta0.35
50-Day Avg53.03
200-Day Avg53.05

About

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEODr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D.
  • Employees11.98K
  • HeadquartersNo. 508, Lujiatan Street, Hangzhou, China, 310051, China
  • Websitehttps://www.tigermedgrp.com

Leadership

  • Dr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D.Co-Founder & Chairman · b. 1963
  • Mr. Zengyu WenPresident, GM & Executive Director · b. 1980
  • Mr. Hao WuCo- President · b. 1967
  • Dr. Xiaochun Cao M.D.Co-Founder & Executive Director · b. 1969
  • Ms. Chengcheng YangSVP & CFO · b. 1974
  • Ms. Xiao Ri LiSecretary · b. 1983
  • Mr. Yifei PengSenior VP & COO
  • Dr. Tianrong Ji M.D., Ph.D.SVP & Chief Investment Officer
  • Xiao Cui ChenAccounting Supervisor
  • Mr. Song MengVP & Chief Technology Officer

Financials

Income Statement

Currency: CNY2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue62.79M122.84M193.26M254.32M336.52M624.56M957.00M1.17B1.69B2.30B2.80B3.19B5.21B7.09B7.38B6.60B6.83B
Growth (%)-+95.63%+57.32%+31.59%+32.32%+85.59%+53.23%+22.73%+43.63%+36.37%+21.85%+13.88%+63.32%+35.91%+4.21%-10.58%+3.48%
Cost of Revenue39.20M63.76M101.10M130.17M184.82M329.00M534.75M727.87M962.61M1.31B1.50B1.68B2.94B4.28B4.54B4.36B4.96B
Gross Profit23.59M59.08M92.16M124.15M151.69M295.56M422.25M446.66M724.43M991.75M1.30B1.51B2.27B2.81B2.85B2.24B1.87B
Gross Margin37.57%48.09%47.69%48.82%45.08%47.32%44.12%38.03%42.94%43.11%46.48%47.43%43.55%39.64%38.53%33.99%27.41%
Operating Expense16.44M24.56M37.10M57.42M49.64M126.10M208.60M247.78M307.60M395.90M218.26M-708.07M-1.43B226.07M358.42M1.58B1.21B
Operating Income7.15M34.53M55.06M66.73M102.06M169.46M213.65M198.89M416.83M595.85M1.08B2.22B3.70B2.58B2.49B664.42M666.64M
Operating Margin11.39%28.11%28.49%26.24%30.33%27.13%22.33%16.93%24.71%25.90%38.69%69.62%70.91%36.45%33.68%10.06%9.76%
EBITDA8.11M36.31M58.18M82.33M127.33M190.31M256.94M257.64M474.33M684.21M1.17B2.35B3.83B2.83B2.80B1.02B1.42B
EBITDA Margin12.92%29.56%30.10%32.37%37.84%30.47%26.85%21.94%28.12%29.74%41.87%73.61%73.40%39.99%37.89%15.39%20.79%
Net Income7.80M31.71M47.79M67.75M94.06M125.50M156.28M140.65M301.01M472.18M841.63M1.75B2.87B2.01B2.02B405.14M887.89M
Net Income Margin12.42%25.81%24.73%26.64%27.95%20.09%16.33%11.98%17.84%20.52%30.02%54.81%55.13%28.32%27.42%6.14%12.99%
R&D---22.13M30.44M9.56M27.54M41.86M49.67M88.03M124.05M156.65M211.83M234.62M261.56M238.39M257.64M
R&D as % of Total Revenue---8.70%9.05%1.53%2.88%3.56%2.94%3.83%4.43%4.91%4.06%3.31%3.54%3.61%3.77%
Interest Expense22.65K39.21K65.51K53.04K12.17M6.58M5.31M10.09M12.54M19.94M41.29M51.37M27.68M89.35M124.13M146.31M90.56M
Interest Expense % of Total Revenue0.04%0.03%0.03%0.02%3.62%1.05%0.55%0.86%0.74%0.87%1.47%1.61%0.53%1.26%1.68%2.22%1.33%

Balance Sheet

Currency: CNY2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets67.39M119.91M186.76M732.84M808.01M1.36B1.61B2.39B3.58B4.68B7.57B19.51B23.74B27.45B29.68B28.67B28.36B
Total Liabilities23.13M24.12M40.73M38.52M52.87M440.72M544.12M548.54M781.85M1.41B2.05B1.65B3.14B4.77B5.23B4.61B4.10B
Total Equity42.37M93.37M141.16M690.06M743.98M863.54M1.00B1.63B2.49B2.84B4.23B16.12B18.12B19.58B21.03B20.67B20.96B
Cash17.42M42.45M85.73M560.81M455.19M432.06M226.56M364.47M536.75M704.49M2.04B10.12B8.54B7.86B7.42B2.06B1.78B
Total Debt-----284.02M266.60M190.91M259.87M712.79M1.04B279.02M899.16M2.58B2.83B2.63B-
Net Debt-17.42M-42.45M-85.73M-560.81M-455.19M-148.04M40.04M-173.56M-276.88M8.30M-1.01B-9.84B-7.65B-5.28B-4.59B579.64M-

Cash Flow

Currency: CNY2009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow21.95M26.59M38.69M14.98M77.10M43.66M185.73M191.91M314.97M522.24M527.56M998.68M1.42B1.36B1.15B1.10B1.12B
Investing Cash Flow-34.17M-20.76M4.64M-22.69M-139.75M-219.46M-413.19M-530.00M-846.40M-366.53M-638.15M-2.37B-2.78B-2.79B-1.53B-4.74B-
Financing Cash Flow019.29M-55.00K482.80M-40.88M122.96M14.10M485.71M702.34M10.01M1.43B9.34B-163.09M809.25M-7.81M-1.70B-
Capital Expenditure13.88M8.29M16.24M21.69M37.45M38.10M87.08M61.66M45.96M91.72M102.91M156.50M368.62M448.60M313.76M356.55M214.37M
Free Cash Flow8.07M18.30M22.45M-6.71M39.65M5.56M98.65M130.25M269.01M430.52M424.65M842.18M1.06B908.90M836.68M740.45M903.72M
Dividends Paid--300.00K681.77K43.12M46.04M47.84M59.12M62.35M126.65M174.64M271.30M261.72M432.46M589.87M642.16M343.66M
FCF to OCF36.77%68.82%58.02%-44.77%51.43%12.73%53.11%67.87%85.41%82.44%80.49%84.33%74.11%66.95%72.73%67.50%80.83%
Dividend Paid to FCF--1.34%-10.16%108.75%828.49%48.49%45.39%23.18%29.42%41.13%32.21%24.80%47.58%70.50%86.73%38.03%

Earnings

Report DateAug 7, 2014Oct 24, 2014Feb 27, 2015Apr 25, 2015Oct 23, 2015Feb 29, 2016Apr 24, 2016Aug 25, 2016Oct 28, 2016Mar 1, 2017Apr 26, 2017Aug 22, 2017Oct 29, 2017Feb 26, 2018Apr 25, 2018Aug 27, 2018Oct 26, 2018Feb 27, 2019Apr 25, 2019Aug 22, 2019Oct 27, 2019Feb 28, 2020Apr 28, 2020Aug 28, 2020Oct 29, 2020Mar 29, 2021Apr 28, 2021Aug 25, 2021Oct 22, 2021Mar 10, 2022Apr 26, 2022Aug 25, 2022Oct 25, 2022Mar 28, 2023Apr 25, 2023Aug 25, 2023Oct 27, 2023Mar 28, 2024Apr 25, 2024Aug 28, 2024Oct 29, 2024Mar 27, 2025Apr 29, 2025Aug 28, 2025Oct 28, 2025Mar 30, 2026Apr 28, 2026Aug 28, 2026
EPS Estimate-------------0.140.120.160.160.180.160.260.130.330.200.280.350.180.360.460.410.450.630.640.660.620.610.650.530.460.490.480.520.220.290.350.340.170.260.19
EPS Actual0.040.050.060.060.050.070.060.050.030.090.060.100.110.130.090.160.130.210.190.280.200.430.150.990.390.490.520.920.611.270.600.780.480.460.660.950.450.170.350.390.29-0.470.190.260.74-0.15-0.15-0.54
Surprise--------------7.14%-25.00%0.00%-18.75%16.67%18.75%7.69%53.85%30.30%-25.00%253.57%11.43%172.22%44.44%100.00%48.78%182.22%-4.76%21.88%-27.27%-25.81%8.20%46.15%-15.09%-63.04%-28.57%-18.75%-44.23%-313.64%-34.48%-25.71%117.65%-188.24%-158.87%-384.21%
TimingAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-market-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketAfter-hours

Key Statistics & Ratios

Market Cap50.28B
Enterprise Value48.30B
Trailing P/E530.91
Forward P/E28.99
PEG Ratio0.00
Price / Sales6.90
Price / Book2.59
EPS0.11
Book Value21.54
Revenue (TTM)7.29B
Gross Profit (TTM)1.92B
EBITDA865.87M
Profit Margin1.25%
Operating Margin11.83%
Return on Equity1.09%
Return on Assets1.43%
Shares Outstanding737.90M
Shares Float646.02M
Beta0.35
Dividend Yield0.22%
Dividend Rate0.13
Payout Ratio0.00%

Dividends

20261×
0.13Jul 10, 2026
20251×
0.30Jun 17, 2025
20241×
0.57Jul 12, 2024
20231×
0.55Jul 7, 2023
20221×
0.50May 31, 2022
20211×
0.30Jun 1, 2021
20201×
0.28May 22, 2020
20191×
0.23Jul 1, 2019
20181×
0.13May 30, 2018
20171×
0.07Sep 19, 2017
20161×
0.07May 20, 2016
20151×
0.13May 20, 2015
20141×
0.13Apr 22, 2014
20131×
0.07May 2, 2013

Stock Splits

  • Jul 1, 20191.5:1
  • May 20, 201520:10
  • Apr 22, 201420:10
  • May 2, 201320:10